iBio, Inc. (IBIO)
| Market Cap | 58.73M |
| Revenue (ttm) | 300,000 |
| Net Income (ttm) | -24.74M |
| Shares Out | 36.14M |
| EPS (ttm) | -1.53 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 644,978 |
| Open | 1.680 |
| Previous Close | 1.710 |
| Day's Range | 1.620 - 1.740 |
| 52-Week Range | 0.556 - 3.820 |
| Beta | 1.36 |
| Analysts | Strong Buy |
| Price Target | 4.75 (+191.41%) |
| Earnings Date | May 14, 2026 |
About IBIO
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cardiometabolic and obesity space. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its... [Read more]
Financial Performance
In fiscal year 2025, iBio, Inc.'s revenue was $400,000, an increase of 77.78% compared to the previous year's $225,000. Losses were -$18.38 million, -26.22% less than in 2024.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for IBIO stock is "Strong Buy." The 12-month stock price target is $4.75, which is an increase of 191.41% from the latest price.
News
iBio, Inc. Transcript: Status update
AI-driven integration with experimental validation accelerates antibody drug discovery, enabling rapid clinic approval and overcoming immune tolerance for challenging targets. Generative models produce compact, functional antigen mimics, and future innovation is expected from simultaneous engineering of both antibody and antigen.
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia
IBIO-600 is a potentially best-in-class, long-acting anti-myostatin monoclonal antibody designed to preserve muscle and improve body composition First participants expected to be dosed in 2Q 2026 SAN ...
iBio, Inc. Transcript: Study update
A bispecific antibody targeting myostatin, activin A, and GDF11 is being developed for PH-HFpEF, aiming for efficacy and improved safety by sparing BMP9, BMP10, and activin B. Preclinical data show promising selectivity and cardiac remodeling benefits, with a development candidate expected by Q3.
iBio to Provide an Update on Cardiopulmonary Program Targeting Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET Company to host corporate update call on Tuesday, March 17, at 4 p.m. ET
iBio, Inc. Transcript: Leerink Global Healthcare Conference 2026
The company is advancing a diversified cardiometabolic pipeline, highlighted by its Activin E antibody program, with key clinical milestones expected over the next 12–18 months. Its AI-enabled platform and strong financial position support rapid development and strategic flexibility. The team’s persistence and integrated approach set it apart in a competitive landscape.
iBio Reports Preclinical Body Composition Data from Obese Non-Human Primates Treated with IBIO-610, a Potential First-in-Class Treatment for Fat-Selective Weight Loss
Study demonstrated reduction of 6.7% visceral fat and 5.2% total fat mass in obese non-human primates (NHPs) despite high-calorie diet Study demonstrated reduction of 6.7% visceral fat and 5.2% total ...
iBio, Inc. Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
The discussion highlighted a robust pipeline targeting obesity and cardiovascular diseases, with multiple assets advancing toward clinical milestones. Key programs focus on muscle preservation, fat-specific weight loss, and improved safety profiles, supported by a strong financial position and experienced leadership.
iBio to Participate in Upcoming Investor Conferences
SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that Martin Brenner, DVM, Ph.D., Chief Executive Officer...
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update
Secured $26 Million in PIPE Financing Led by a Top-Tier Biotech Investor to Advance Preclinical Programs and Extend Cash Runway
iBio Announces $26 Million Private Placement
SAN DIEGO, Jan. 09, 2026 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that it has entered into a securities purchase agreement ...
iBio, Inc. Transcript: Evercore ISI 8th Annual HealthCONx Conference
Management outlined a portfolio of long-acting antibody programs targeting obesity and related diseases, leveraging AI-driven discovery and a dual Australia-U.S. regulatory path. Key milestones include IND filings, first-in-human trials, and strategic partnerships, supported by a strong cash position.
iBio to Participate in the 8th Annual Evercore Healthcare Conference
SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the 8th Annual Evercore Heal...
iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update
Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Prese...
iBio, Inc. Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
The company has evolved from vaccine development to a platform-based biotech targeting obesity with a diversified antibody portfolio. Key assets are advancing toward clinical milestones, supported by strong financials and selective partnerships. Major data readouts and filings are expected from 2024 to 2027.
iBio Unveils New Non-Human Primate Data on IBIO-610, an Activin E Antibody with Strong Therapeutic Potential for Fat-Selective Weight-Loss and Weight Maintenance
Previously reported data showed that in a diet-induced obesity mouse model, IBIO-610 drives fat-selective, GLP-1-synergistic weight loss and prevents weight regain following GLP-1 treatment discontinu...
iBio to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
SAN DIEGO, Oct. 23, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced that it will participate in the Guggenheim 2nd Annual He...
iBio to Present New Preclinical Data on Its Activin E Antibody at Two Upcoming Scientific Conferences, ObesityWeek® and PEGS Europe 2025
SAN DIEGO, Oct. 21, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced that Cory Schwartz, Ph.D., Director of Research and Early...
iBio Reports Fiscal Year 2025 Financial Results and Provides Corporate Update
SAN DIEGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NASDAQ:IBIO), an AI-driven innovator of precision antibody therapies, today announced its financial results for the fiscal year ended June 30,...
iBio Announces Closing of $50 Million Public Offering
Total gross proceeds of $100 million if all Series G warrants and Series H warrants are exercised for cash Financing was led by Balyasny Asset Management and included participation from Cormorant Asse...
iBio Announces Pricing of $50 Million Public Offering
SAN DIEGO, Aug. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced the pricing of an underwritten public offering (the “off...
iBio Announces Proposed Public Offering
SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (Nasdaq: IBIO), an AI-driven innovator of precision antibody therapies, today announced it has commenced an underwritten public offering (the “o...
iBio, Inc. Transcript: Study Update
Next-generation antibody programs are advancing for obesity, targeting muscle preservation, fat-specific weight loss, and improved tolerability. Lead assets iBio 600 and iBio 610 show strong preclinical efficacy, with clinical entry planned for 2026 and new amylin receptor candidates progressing rapidly.
iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results
Lead amylin receptor agonist engineered antibody significantly reduced acute food intake in a mouse model of obesity, comparable to the efficacy of a leading amylin peptide agonist
iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call
Review of promising Myostatin and Activin E antibody data iBio to announce 3 rd target in Astral Bio Collaboration Conference call Tuesday, June 24 at 8:30 a.m. ET SAN DIEGO, June 23, 2025 (GLOBE NEWS...
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment
iBio nominates IBIO-610 as development candidate for its first-in-class Activin E antibody New study aims to evaluate the half-life of IBIO-610 in obese, elderly non-human primates (NHP) and assess ea...